Selexys develops novel therapeutics for the treatment of inflammatory and thrombotic diseases.
Business Model:
Revenue: $8.5M
Employees: 51-200
Selexys Pharmaceuticals was acquired by
Novartis.
The acquisition happend on 2016-11-21.
Details of the transaction were not public
Address: 840 Research Pkwy
City: Oklahoma City
State: OK
Zip: 73104
Country: US
Selexys develops novel therapeutics for the treatment of inflammatory and thrombotic diseases.
Contact Phone:
+14053198195
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2009 | Debt Financing | $3.4M | 11/2010 | Debt | $5M | 1/2009 | Seed Round | 2 | - |
i2E Oklahoma Seed Capital Fund i2E Oklahoma Seed Capital Fund |
9/2012 | Series A | 1 | $23M |
MPM Capital MPM Capital |
9/2012 | Series A | $43.2M | 8/2008 | Debt | $3.4M | 11/2011 | Debt Financing | $5M | 2/2015 | Series B | $43.2M | 1/2009 | Seed Round | 2 | - |
i2E Oklahoma Seed Capital Fund i2E Oklahoma Seed Capital Fund |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|